Young-Ho Lee
Up to now most of the cells used in cell therapeutics have been mesenchymal stem cells (MSCs). However, mononuclear cells (MNCs) from cord blood (CB) or G-CSF (granulocyte-colony stimulating factor)-mobilized peripheral blood (mPB) MNCs could be an alternative option because MNCs contain both HSCs (hematopoietic stem cells) and MSCs. In addition, cellular components other than purified HSCs or MSCs could play important roles in tissue regeneration. The optimal route of administration in cell therapy is another important issue. The therapeutic benefits and clinical availability of intravenous infusion of CB- or mPB-MNCs in the field of cell therapy will be briefly reviewed.